Exploring New Frontiers in Cancer Treatment: The Expanded Role of Cellular Therapies

With an increasing number of different types of cellular therapies being approved by the FDA for both hematologic malignancies and solid tumors, it is important for clinicians to be informed about the current and emerging cell-based therapies that impacts clinical practice. Continuing education on the importance of emerging cellular therapies and how they are integrated in clinical practice will help clinicians make strategic decisions to ensure desirable patient outcomes.

Target Audience

This program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, PAs, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Describe the existing and emerging cellular therapies in the hematologic malignancies and solid tumor space.
  • Understand the benefits and implications of using different types of cellular therapies in the clinic.
  • Discuss multidisciplinary strategies to utilize these cell-based therapies and address toxicity in treatment planning.

You may also be interested in

CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies

Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities.
CRS and ICANS Management in CAR T/Bispecific Antibody Therapies
As these therapies continue to evolve, it is imperative that nursing policies are created/revised and shared with nursing staff to remain up to date on current clinical practice for these complications. With continued education and reinforcement of protocols, nurses can positively impact patient outcomes.
Refining Therapeutic Approaches in Relapsed/Refractory Multiple Myeloma: Expert Guidance on Bispecific Antibody Therapy Optimization
Expert faculty provide a comprehensive overview of bispecific antibodies in relapsed/refractory multiple myeloma, including clinical considerations, common toxicities, and prophylaxis and management strategies.
Additional information
Supporters: 

This activity is supported by educational grants from Coherus BioSciences; Genentech, a member of the Roche Group; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Novartis. This activity is supported by an independent medical education grant from AbbVie. This educational activity is supported by an independent medical education grant from GSK. This activity is supported by a grant from Pfizer, Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
06/30/2025
Course expires: 
03/01/2026
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2025 Oncology Fellows Program: New Horizons in Quality Cancer Care™

Shailender Bhatia, MD
Fred Hutchinson Cancer Center

Christopher R. D'Angelo, MD
Fred & Pamela Buffett Cancer Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Wui-Jin Koh, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Shailender Bhatia, MD
Bristol Myers Squibb: Consulting Fee
Replimune Group Inc.: Consulting Fee

Christopher R. D'Angelo, MD
AbbVie, Inc.: Consulting Fee; Grant/Research Support
BeiGene: Consulting Fee
Bristol Myers Squibb: Consulting Fee; Grant/Research Support
Curis, Inc.: Consulting Fee; Grant/Research Support
Fate Therapeutics: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Genmab: Consulting Fee; Grant/Research Support
Ono Pharmaceutical Co., Ltd.: Consulting Fee

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-25-094-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 1, 2026. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing